| [1] |
de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J].J Clin Oncol,2000,18(16): 2938-47.
|
| [2] |
Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer[J].Cancer Chemother Pharmacol, 19 90,25(4):299-303.
|
| [3] |
Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures[J].Semin Oncol,2002,29(5 Suppl 15):21-33.
|
| [4] |
Ibrahim A, Hirschfeld S, Cohen MH, et al. FDA drug approval summaries: oxaliplatin[J]. Oncologist,2004,9(1):8-12.
|
| [5] |
Cavaletti G, Tredici G, Petruccioli MG, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat[J]. Eur J Cancer,2001,37(18):2457-63.
|
| [6] |
McKeage MJ, Hsu T, Screnci D, et al. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs[J]. Br J Cancer,2001,85(8):1219-25.
|
| [7] |
Yang Y, Wang Y, Li S, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia[J]. J Med Genet,2004, 41(3):171-4.
|
| [8] |
Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain[J].Nature,2006,444 (7121):894-8.
|
| [9] |
Fertleman CR, Baker MD, Parker KA, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes[J]. Neuron, 2006,52(5):767-74.
|
| [10] |
Chaplan SR, Bach FW, Pogrel JW, et al. Quantitative assessment of tactile allodynia in the rat paw[J]. J Neurosci Methods,1994,53 (1) :55-63.
|
| [11] |
Xing GG,Liu FY,Yao L, et al. Changes in long-term synaptic plasticity in the spi nal dorsal horn of neuropathic pain rats[J]. Beijing Da Xue Xue Bao (Yi Xue Ban),2003,35(3): 226-30.[邢国 刚, 刘风雨, 姚磊,等. 神经病理痛大鼠脊髓背角突触传递的长 时程可塑性变化[J].北京大学学报(医学版),2003,35(3):226-30.]
|
| [12] |
Rush AM, Dib-Hajj SD, Liu S, et al. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons[J]. Proc Natl Acad Sci U S A,2006,103(21):8245-50.
|
| [13] |
Djouhri L, Newton R, Levinson SR, et al. Sensory and electrophysiological properties of guinea-pig sensory neurones expressing Nav 1.7 (PN1) Na+ channel alpha subunit protein[J]. J Physiol,2003,546(Pt 2):565-76.
|
| [14] |
Fukuoka T, Kobayashi K, Yamanaka H, et al. Comparative study of the distribution of the alpha-subunits of voltage-gated sodium channels in normal and axotomized rat dorsal root ganglion neurons[J]. J Comp Neurol,2008,510(2):188-206.
|
| [15] |
Ahn HS, Black JA, Zhao P, et al. Nav1.7 is the predominant sodium channel in rodent olfactory sensory neurons[J]. Mol Pain,2011,7:32.
|
| [16] |
Weiss J, Pyrski M, Jacobi E, et al. Loss-of-function mutations in sodium channel Nav1.7 cause anosmia[J]. Nature,2011,472(7342): 18 6-90.
|
| [17] |
Catterall WA, Goldin AL,Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels[J]. Pharmacol Rev,2005,57(4):397-409.
|
| [18] |
Klugbauer N, Lacinova L, Flockerzi V, et al. Structure and functional expression of a new member of the tetrodotoxinsensitive voltage-activated sodium channel family from human neuroendocrine cells[J]. EMBO J,1995,14(6):1084-90.
|
| [19] |
Cummins TR, Howe JR,Waxman SG. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel[J]. J Neurosci,1998,18 (23) :9607-19.
|
| [20] |
Herzog RI, Cummins TR, Ghassemi F, et al. Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons[J]. J Physiol,2003,551(Pt 3):741-50.
|
| [21] |
Rush AM, Cummins TR,Waxman SG. Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons[J]. J Physiol,2007, 579(Pt 1):1-14.
|
| [22] |
Black JA, Frézel N, Dib-Hajj SD, et al. Expression of Nav1.7 in DRG neurons extends from peripheral terminals in the skin to central preterminal branches and terminals in the dorsal horn[J]. Mol Pain,2012,8:82.
|
| [23] |
Ling B, Coudoré-Civiale MA, Balayssac D, et al. Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat[J]. Toxicology,2007,234(3): 17 6-84.
|
| [24] |
Carrato A, Gallego J, Díaz-Rubio E. Oxaliplatin: results in colorectal carcinoma[J]. Crit Rev Oncol Hematol,2002,44(1):29-44.
|
下载:
